Monthly oral ibandronate 100 mg is as effective as monthly intravenous ibandronate 1 mg in patients with various pathologies in the MOVEST study
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Bone and Mineral Metabolism"
DOI: 10.1007/s00774-017-0839-2
Abstract: The non-inferiority of oral ibandronate 100 mg to intravenous (i.v.) ibandronate 1 mg in increasing lumbar spine (LS) bone mineral density (BMD) after 12 months of treatment was demonstrated in the randomized, phase III MOVEST study. We conducted… read more here.
Keywords: ibandronate; oral ibandronate; ibandronate patients; study ... See more keywords